Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway
Donglai Chen(Sun Yat-sen University), Yongbing Chen(Soochow University), Lichen Yin(Soochow University), Hua He(Soochow University), Jinhui Wang(Wenzhou Medical University), Chang Chen(Shanghai Pulmonary Hospital), Rongying Zhu(Soochow University), Fuquan Zhang(Second Affiliated Hospital of Soochow University), Shanzhou Duan(Soochow University)
Cited by 48
Related Papers
Development and Validation of a Deep Learning Model for Non–Small Cell Lung Cancer Survival
|JAMA Network Open|2020|272
Choice of Surgical Procedure for Patients With Non–Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study
|Journal of Clinical Oncology|2016|245
Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
|Journal of Experimental & Clinical Cancer Research|2019|221
Biomedical polymers: synthesis, properties, and applications
|Science China Chemistry|2022|187